XNCR240816C20000
- 1.50
- 0.000.00%
Xencor Newsroom
Form 144 | Xencor(XNCR.US) Officer Proposes to Sell 665.51K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 9, $Xencor(XNCR.US)$ Officer Desjarlais John R intends to sell 36,329 shares of its common stock on Jul 9, with a total market value of approximately $665.51K. Source:
Xencor Insiders Sold US$891k Of Shares Suggesting Hesitancy
Xencor, Inc. (NASDAQ:XNCR) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. When analyzing insider transactions, it is usually more valuable to
Xencor (NASDAQ:XNCR) Shareholders Have Endured a 52% Loss From Investing in the Stock Five Years Ago
Peeling Back The Layers: Exploring Xencor Through Analyst Insights
In the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:XNCR), showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings, showcasing the evolvi
Express News | Raymond James Maintains Strong Buy on Xencor, Lowers Price Target to $40
Xencor Is Maintained at Outperform by RBC Capital
Xencor Is Maintained at Outperform by RBC Capital
BMO Capital Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $32
BMO Capital analyst Etzer Darout maintains $Xencor(XNCR.US)$ with a buy rating, and adjusts the target price from $34 to $32.According to TipRanks data, the analyst has a success rate of 58.7% and a t
Express News | Xencor Inc : BMO Cuts Target Price to $32 From $34
RBC Trims Price Target on Xencor to $31 From $32, Maintains Outperform, Speculative Risk Rating
Xencor (XNCR) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $21 to $50.
Express News | Xencor Inc : RBC Cuts Target Price to $31 From $32
Express News | Xencor Inc : Wedbush Cuts Target Price to $34 From $36
Xencor: J&J's Janssen Termintates Rights to Plamotamab
Xencor on Thursday said Johnson & Johnson's Janssen unit has terminated its rights to the tumor-targeted antibody plamotamab under a collaboration and license agreement the companies inked in 2021.
Express News | Xencor- Janssen Retained Rights to Develop B-Cell Targeting Cd28 Bispecific Antibodies, Including Jnj-9401 (Psma X Cd28), Jnj-1493 (Cd20 X Cd28)
Express News | Xencor Inc - Has Been Notified That Janssen Will Terminate Its Rights to Plamotamab Under Collaboration and License Agreement
Express News | Xencor Inc - Will Regain Exclusive Worldwide Rights to Plamotamab, a Cd20 X Cd3 Bispecific T-Cell Engager
Xencor Regains CD20 X CD3 Bispecific T-Cell Engager
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues
Xencor, Inc.'s (NASDAQ:XNCR) price-to-sales (or "P/S") ratio of 8.3x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies
Vir Gains on Early Mid-stage Data for Hepatitis Candidate
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Buy Rating Affirmed for Xencor: Strong Q1 Financials, FDA Approval, and Promising Pipeline Signal Growth Potential